title: A monoclonal antibody against Schistosoma haematobium soluble egg antigen: efficacy for diagnosis and monitoring of cure of S. haematobium infection.
abstract: A monoclonal antibody (mAb), 2F/11F, raised against Schistosoma haematobium soluble egg antigen (SEA) was found to be nonreactive with S. mansoni SEA or other parasite antigens (Fasciola hepatica, Echinococcus granulosus). This IgG1 mAb recognized a repetitive epitope on S. haematobium SEA in the molecular-weight regions of 70, 42, and 35 kDa. It was employed as both an antigen-capture and a biotinylated detection antibody in a sandwich enzyme-linked immunosorbent assay (ELISA) for the detection of circulating schistosome antigen (CSA) and had a detection limit of <1 ng S. haematobium SEA/ml. CSA levels were measured in serum and urine samples from 116 S. haematobium-infected rural students before therapy and at 4, 8, and 12 weeks after praziquantel treatment. Serum and urine samples from 50 S. mansoni -infected patients, 15 patients harboring other parasites, and 30 noninfected individuals were also assessed. CSA was detected in 90.5% of serum samples and 94% of urine samples from S. haematobium-infected patients. CSA was undetectable in serum from the 15 patients harboring other parasites and in 94% of serum samples and 84% of urine samples from S. mansoni-infected patients. In the S. haematobium-infected group a positive correlation was detected between CSA levels in serum and urine samples and the egg load per 10 ml urine. A significant reduction in CSA levels was detected in serum and urine samples after praziquantel therapy. CSA was undetectable in 87% of serum samples and 81.5% of urine samples from schistosomiasis haematobium patients at 12 weeks post-treatment. These data demonstrate that the use of mAb 2F/11F for detection of CSA provides a sensitive method for the immunodiagnosis and monitoring of cure of schistosomiasis haematobium.
authors.affiliation: Department of Immunology, Theodor Bilharz Research Institute, Warak El Hadar, Imbaba, Guiza, Cairo, Egypt.
authors.forename: F
authors.initials: F
authors.lastname: Salah
authors.forename: Z
authors.initials: Z
authors.lastname: Demerdash
authors.forename: Z
authors.initials: Z
authors.lastname: Shaker
authors.forename: A
authors.initials: A
authors.lastname: El Bassiouny
authors.forename: G
authors.initials: G
authors.lastname: El Attar
authors.forename: S
authors.initials: S
authors.lastname: Ismail
authors.forename: N
authors.initials: N
authors.lastname: Badir
authors.forename: A S
authors.initials: AS
authors.lastname: El Din
authors.forename: M
authors.initials: M
authors.lastname: Mansour
mesh_terms: D000818:Animals; D000909:Antibodies, Helminth / Q000096:biosynthesis / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000276:immunology; D000947:Antigens, Helminth / Q000097:blood / Q000276:immunology / Q000652:urine; D019921:Biotinylation; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D010270:Parasite Egg Count; D011223:Praziquantel / Q000627:therapeutic use; D012548:Schistosoma haematobium / Q000254:growth & development / Q000276:immunology* / Q000302:isolation & purification*; D012550:Schistosoma mansoni / Q000276:immunology; D012553:Schistosomiasis haematobia / Q000175:diagnosis* / Q000188:drug therapy; D012556:Schistosomicides / Q000627:therapeutic use
chemical_list: D000909:Antibodies, Helminth; D000911:Antibodies, Monoclonal; D000947:Antigens, Helminth; D012556:Schistosomicides; D011223:Praziquantel